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Induced pluripotent stem cells (iPSCs) are somatic cells reprogrammed into an 
embryonic-like pluripotent state by the expression of specific transcription 
factors. iPSC technology is expected to revolutionize regenerative medicine in 
the near future. Despite the fact that these cells have the capacity to self-renew, 
they present low efficiency of reprogramming. Recent studies have demonstrated 
that the previous somatic epigenetic signature is a limiting factor in iPSC 
performance. Indeed, the process of effective reprogramming involves a complete 
remodeling of the existing somatic epigenetic memory, followed by the 
establishment of a “new epigenetic signature” that complies with the new type 
of cell to be differentiated. Therefore, further investigations of epigenetic 
modifications associated with iPSC reprogramming are required in an attempt 
to improve their self-renew capacity and potency, as well as their application in 
regenerative medicine, with a new strategy to reduce the damage in degenerative 
diseases. Our review aimed to summarize the most recent findings on epigenetics 
and iPSC, focusing on DNA methylation, histone modifications and microRNAs, 
highlighting their potential in translating cell therapy into clinics.
Keywords: induced pluripotent stem cells, regenerative medicine, cell reprogramming, 
epigenetics, histones, microRNAs.
introduction
Human embryonic stem cells have great potential for 
self-renewal and the ability to differentiate into all tissues 
of the body (except embryonic attachments),1 forming an 
important source of material for regenerative medicine 
and cell therapy. However, the use of embryonic stem cells 
is limited by ethical and religious conflicts, as well as im-
munological incompatibility.2 In order to reduce the dam-
age caused by degenerative diseases, different strategies 
are being used in an attempt to optimize the use of em-
bryonic stem cells. 
The first strategy used was that of somatic cell nucle-
ar content (SCNT) for unfertilized and enucleated oo-
cytes.3 However, the yield of this technique is still very low 
and the cells obtained can present phenotypic and gene 
expression abnormalities.4 Another strategy is the fusion 
of somatic cells with embryonic cells, reprogramming 
their genome.5 However, although fusion-induced repro-
gramming is very efficient (about 95%), the resulting hy-
brid cells lack therapeutic potential due to their tetra-
ploidy, as well as the presence of exogenous genes from 
the pluripotent cells used in the fusion.5 Therefore, a 
search for new strategies for the efficient use of cells with 
an embryonic profile is still needed.
In 2006 Takahashi and Yamanaka managed to induce 
pluripotency in mouse fibroblasts (MEF) from the expres-
sion of four embryonic transcription factors (Oct4, Sox2, 
Klf4, c-Myc), currently known as OSKM or “Yamanaka 
factors.” These cells were called induced pluripotent stem 
cells (iPSCs).6 The iPSC are similar to embryonic cells in 
terms of morphology, gene expression, differentiation 
status and epigenetic pattern, both in culture, as well as 
in vivo.7 This mechanism of reprogramming somatic cells 
into embryonic stem cells resulted in the Nobel Prize in 
Induced plurIpotent stem cells reprogrammIng: epIgenetIcs and applIcatIons In the regeneratIve medIcIne
rEv assoc mEd Bras 2017; 63(2):180-189 181
medicine for Yamanaka in 2012, shared with John b. Gur-
don.8 Since then, several surveys have been developed to 
explore this technology. In fact, several researchers were 
able to reprogram somatic cells (postmitotic) into iPSC 
using the aforementioned strategy.9-11
The advantage of using this method is that it allows 
the derivation of pluripotent cells from the donor, reduc-
ing the risk of rejection by the immune system. In addition, 
this method provides a platform to study the molecular 
mechanisms of genetic and chronic diseases, minimizing 
the ethical, religious and political conflicts and opening 
up new perspectives for regenerative medicine. However, 
although cell identity can be modified by the ectopic ex-
pression of transcription factors, the efficiency of repro-
gramming remains low (0.1 to 3%) and its cost is high.11,12
The low reprogramming efficiency of iPSC is associ-
ated with residual epigenetic memory of the tissue from 
which they were derived, which complicates the repro-
gramming process. Recent studies show that despite iPSC 
sharing common characteristics of pluripotency and 
self-renewal capacity, these cells still retain an epigenetic 
memory.13-15 In addition, there is evidence that the repro-
gramming process involves complete remodeling of the 
existing somatic epigenetic memory, followed by the es-
tablishment of a new “epigenetic signature” that conforms 
to the type of cell to be differentiated.16 Therefore, the 
epigenetic memory becomes a barrier in the process of 
cellular reprogramming. This fact highlights the need for 
new studies investigating the epigenetic changes associ-
ated with cellular reprogramming in an attempt to im-
prove the efficiency and effectiveness of the iPSC created, 
as well as their clinical application. As such, our review 
aimed to gather information about the epigenetic factors 
(DNA methylation, changes to histones and microRNAs) 
associated with iPSC reprogramming efficiency. In addi-
tion, we have brought together the clinical studies using 
iPSC as cell therapy.
epigenetics and ipsc
Waddington was the first researcher to use the term epi-
genetics in 1942 to explain how the genome interacts with 
the environment during the development process.17 There-
fore, any reversible and inheritable change in the func-
tional genome that does not alter the sequence of DNA 
nucleotides refers to epigenetics.18 Several pathologies are 
associated with epigenetic changes.19-22 
The reprogramming efficiency of iPSC is also direct-
ly related to epigenetic changes such as DNA methylation 
and the epigenetic memory of the source cells.23 The iPSC 
reprogramming process can be divided into three distinct 
phases, called pre-iPSC, intermediate and full reprogram-
ming. The reprogramming process is extremely slow, with 
low efficiency (0.1 to 3%) and high cost,11,12 and depends 
on suitable levels of gene expression in each phase and 
specific epigenetic changes.24 Djuric and Ellis compared 
the epigenetic changes that occur during the reprogram-
ming process with a “seven headed dragon,” where a series 
of changes is necessary for efficient reprogramming, 
namely: 1) Endogenous reactivation of genes related to 
cell pluripotency, Nanog and Oct4; 2) Chromatin chang-
es, such as trimethylation in H3K27 and changes in H3K4; 
3) Hypomethylation of heterochromatin; 4) Reactivation 
of the inactive X chromosome; 5) Maintenance of DNA 
methylation marks; 6) Silencing the retrovirus that in-
duces pluripotency; and, finally, 7) Two- or three-dimen-
sional chromatin changes and location of nuclear sub-
domains.24 Therefore, the control of epigenetic factors 
during reprogramming may improve the induction of 
iPSC and their efficiency.25
epigenetic changes in ipsc reprograMMing
DNA methylation in iPSC reprogramming
DNA methylation is an epigenetic mechanism involved 
in many important cellular processes such as cell prolif-
eration and differentiation, transcriptional repression, 
genomic imprinting, organization of chromatin and in-
activation of the X chromosome.26 Thus, changes in the 
DNA methylation profile are associated with the appear-
ance of many degenerative diseases.
Studies show that DNA methylation is considered a 
crucial epigenetic barrier in the reprogramming of iPSC.27-31 
For the expression of genes essential for reprogramming, 
such as Oct3/4 and Nanog, demethylation of cytosines is 
necessary in the respective promoter regions.32 Thus, in-
hibition of methylation by enzymes or interfering RNA 
may be an option to improve this process.33 Mikkelsen et 
al. showed that the use of 5-azacytidine (AZA) inhibits the 
enzyme DNA methyltransferase 1, assisting in DNA de-
methylation, which may favor the reprogramming of 
iPSC.33 Another study noted an improvement in repro-
gramming efficiency using DNA hydroxylase (Tet1), an 
enzyme that is able to oxidize 5-methylcytosine and, after 
subsequent replications, promotes DNA demethylation 
by reactivating Oct4 gene transcription, favoring the re-
programming process.31 In addition to the use of AZA and 
the enzyme Tet1, other researchers have used ascorbic acid 
(vitamin C). Vitamin C acts as a cofactor, stimulating 
hypomethylation and consequently increasing the activ-
ity of histone H3K36 demethylase. This process results in 
an improvement of cellular reprogramming efficiency.34-36
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The aforementioned studies demonstrate the impor-
tance of DNA demethylation in cell reprogramming. Sev-
eral studies have attempted to improve these and other 
epigenetic mechanisms in order to improve both the 
quality and efficiency of iPSC reprogramming. Another 
relevant topic for such improvement is the change in 
histones during the reprogramming process.
Changes to histones in iPSC reprogramming
Histones are basic proteins rich in lysine and may suffer 
several epigenetic changes. Most of these modifications 
happen in the N-terminal region of the histone, with the 
exception of ubiquitination, which occurs in the C-ter-
minal region of H2A and H2B.37 Epigenetic modifications 
to histones may either promote or inhibit gene transcrip-
tion by changing the level of chromatin folding.38,39
Taking into consideration the epigenetic changes in 
histones in iPSC, H3 is the histone researched the most, 
as it is directly related to genes expressed during embry-
onic development, such as Oct3/4, Sox2 and Nanog. It 
has already been demonstrated that methylation of H3K27 
is associated with the suppression of various genes, and 
that persistent trimethylation of the lysine 27 of histone 
3 (H3K27me3) blocks reprogramming by repressing the 
chromatin region associated with the target genes of the 
stem cells. However, the methylation of H3K4 is associ-
ated with the activation of different embryonic genes.24 
In an attempt to improve the performance of iPSC and 
reach the ideal conditions for the induction of pluripo-
tency, by reducing the “epigenetic memory” in somatic 
cells, different strategies that directly or indirectly affect 
the methylation/acetylation of H3 have been used.12 Sev-
eral researchers have demonstrated that it is possible to 
perform the induction of pluripotency without the use 
of Yamanaka factors, using only chemical compounds/
molecules that interfere with the enzymes that control 
the chromatin structure.40
Recently, Rais et al. showed that the inhibition of 
Mbd3 – a subunit of the NuRD complex responsible for 
the deacetylation of histones, remodeling of nucleosomes 
and gene expression inhibition – is able to reactivate the 
genes expressed during embryonic development and im-
prove the efficiency of iPSC reprogramming by almost 
90%, both in human as well as mouse cells.41 
Many other strategies have been tested in order to 
improve the iPSC reprogramming process, such as the 
use of small molecules like Forskolin (FSK),42 BIX-01294,43 
valproic acid (VPA – HDAC histone deacetylase inhibitor)44 
and vitamin C.45 Therefore, the induction of pluripo-
tency of iPSC can only occur with the use of small mol-
ecules.46-48 The authors advocate the use of such because 
they are not immunogenic, with greater yield and easy 
production. Thus, the use of chromatin modulators can 
increase efficiency in the iPSC reprogramming process.49 
To do so, it is necessary to use a small molecule that is 
able to demethylate the DNA in the promoter region and 
change specific regions in histones.
MicroRNAs in iPSC reprogramming
MicroRNA or miRNA are important tools for regulating 
gene expression in post-transcriptional iPSC by promot-
ing pluripotency to modulate the stability of messenger 
RNA (mRNA) and suppress the signs of differentiation 
during the self-renewal of embryonic stem cells. 
MiRNAs also modulate the signaling cascades that 
are necessary for maintaining the pluripotent state.50 
Wang et al. noted that the loss of function in the enzyme 
Dicer and DGCR8, proteins essential for the biogenesis 
of microRNAs in the embryonic stem cells of mice, pres-
ent two different phenotypes: 1) reduction in proliferation 
due to cell cycle arrest in G1; and 2) resistance to differ-
entiation, which reveals a close relationship between mi-
croRNAs, differentiation and the pluripotency of cells.51,52
MicroRNAs are small non-coding RNA molecules. They 
have 18-25 nucleotides (nt), and are derived from a larger 
precursor. The processing of microRNAs occurs as follows:
1. After DNA transcription by RNA polymerase II or III 
the primary microRNA is formed (pri-miRNA). This 
may be presented in the shape of a fork. The pri-miRNA 
first undergoes processing by the enzyme ribonucle-
ase (RNase) nuclear III-like DROSHA. The specifici-
ty of the cleavage in this step is guided by the DGCR8 
protein, which acts as a “molecular ruler,” position-
ing the DROSHA at a distance of 11 nucleotides from 
the base of the pri-miRNA loop. After cleavage, a pre-
miRNA (precursor miRNA) is released, formed by 
about 60-70 nt.53
2. The pre-miRNA is actively transported to the cyto-
plasm by exportin-5 (Exp5), when this protein is linked 
to its Ran-dependent GTP cofactor. In the cytoplasm, 
it undergoes another cleavage process, where it loses 
the loop and is reduced to a miRNA duplex approx-
imately 18-25pb in length. This last stage of process-
ing is conducted by DICER, an RNAse-III type en-
zyme, aided by the TRBP protein.53
3. Finally, the RNA-binding protein TRBP recruits a 
multimeric complex denominated RISC (RNA-in-
duced silence complex), which includes the protein 
Argonaute 2 (in mammals) as the main component. 
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Only one of the microRNA duplex strands remains 
in the RISC complex (guide strand), with the other 
being degraded (passenger strand). The RISC com-
plex is able to identify and bind to target messengers 
RNAs in region 3’UTR through complementarity of 
bases in the “SEED” region of the miRNA (nucleo-
tides 2-8 from the 5’ end) in order to inhibit its trans-
lation or promote its adenylation and degradation.53 
MicroRNAs that promote the reprogramming of iPSC
 • miR 290-295 (cluster): These constitute more than 
70% of the entire population of microRNAs in the 
embryonic stem cells of mice. miR 291-3 p, miR-294 
and miR-295 are part of this cluster and indirectly 
promote the transition of genes associated with en-
try into the G1-S phase, blocking Cdkna (p21), a sup-
pressor of the Cyclin E/Cdk2 complex, and regulator 
of the cell cycle. After its transfection into MEFs there 
is an increase of 0.01-0.05% to 0.1-0.3% in cell repro-
gramming efficiency.54
 • miR 302-367 and miR 371-373 (cluster): These miRNAs 
suppress the expression of MBD2 (methyl-CPG-bind-
ing domain protein 2), which works like a demethyl-
ase in cells, resulting in increased expression of Nanog 
and conversion of completely reprogrammed iPSC. 
They are also able to reduce expression of the inhib-
itors in the G1-S phase, as well as increasing the ki-
netics of the mesenchymal-epithelial transition (MET) 
required for reprogramming.55,56 Only the use of miR-
302a/b/c/d and miR-367 is able to reprogram adult 
cells, and with greater efficiency, when compared to 
the Yamanaka method.57 Data demonstrate that miR-
302 in conjunction with Yamanaka factors inhibits 
NR2F2 (nuclear receptor subfamily 2, group F, mem-
ber 2) and improves reprogramming efficiency through 
indirect positive regulation of Oct4.58
 • miR-200b and -200c, miR-205: These promote MET 
via signaling of transforming growth factor β (TGF-β) 
and, in conjunction with the Yamanaka factors, exclude 
the need for signaling of bone morphogenetic protein 
(BMP) during the initial reprogramming phase.59
 • miR-93, miR-106: They suppress the expression of 
TGF-β and p21, leading to MET and increased pro-
liferation.60 
 • miR-135b: This is highly expressed during the repro-
gramming process, regulating the expression of TGF-β, 
IGFBP5 (insulin-like growth factor binding protein 5) 
and Wisp1 (inducible-signaling pathway protein 1), 
which are involved in the expression of extracellular 
matrix genes.61
MicroRNAs that are barriers to iPSC reprogramming
 • miR Let-7 (cluster): This inhibits the Pou5f1/Oct4, 
Sox2, Nanog and Tcf3 targets – pluripotency factors 
– stabilizing a differentiated state. In addition, this 
miRNA inhibits the translation of CDK4, repressing 
the transition of the G1-S-phase. MiR Let-7 forms a 
negative feedback circuit, providing a molecular mech-
anism that facilitates the decision between self-re-
newal and differentiation of cells.50,62
 • miR-34a, miR-34b/c: miR-34a represses the expres-
sion of Nanog, Sox2 and c-Myc. Taken in conjunction, 
miR-34a and miR-34b/c target p53 (tumor suppres-
sor gene), holding an essential role in the containment 
of somatic reprogramming.63
These studies show that miRNAs can be important tools 
in the mediation of iPSC reprogramming without the 
need for the ectopic expression of pluripotency induction 
factors, including OSKM factors. The tables below pres-
ent a summary of different approaches and their effects 
on iPSC reprogramming. Table 1 is related to changes 
in DNA methylation, Table 2 is related to modifications 
in histones and Table 3 is related to the use of miRNAs. 
In addition, Figure 1 presents these changes in summa-
rized form.
clinical application of ipscs
The main discussion about the use of iPSC in regenerative 
medicine is related to their ability to transform into can-
cer cells. Incomplete reprogramming of iPSC may be as-
sociated with the emergence of various mutations.
In addition to the impact on iPSC reprogramming, 
OSKM factors are associated with the development of 
tumors. Oct4 is highly expressed in the cervical cancer 
cell line. Deletion of Sox2 is associated with regression of 
melanomas. The Klf4 and c-Myc factors regulate genes 
involved in cell growth and proliferation.64 However, over 
the last 10 years following the discovery of iPSC, this 
technology has undergone several changes, such as the 
use of episomal plasmids that are not integrated into the 
genome, diminishing the carcinogenic potential of these 
cells.65 Currently, several methods are used to develop 
iPSC lines, including the use of plasmids, transposons, 
adenovirus, Sendai virus, miRNA and chemical com-
pounds, minimizing mutagenic factors. Given these ad-
vances, iPSC have been used in pre-clinical tests and 
clinical trials. 
The first transplant of iPSC in humans occurred in 
Japan in the second half of 2014, in a 70-year-old patient 
with age-related macular degeneration (AMD). This pa-
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TABLE 1 Epigenetic DNA changes.
Authors Year Species Type of cell Technology Epigenetic changes Results
Mikkelsen et al.33 2008 Mice Fibroblasts 5-azacytidine 
(AZA)
Inhibitor of DNA 
methyltransferase
Promotes the demethylation of 
pluripotency genes
Mikkelsen et al.33 2008 Mice Fibroblasts shRNA/siRNA Reduced expression of 
DNMT1 using siRNA/shRNA
Demethylation and complete 
reprogramming of cells
Popp  et al.28 2010 Mice Embryonic AID DNA demethylation Clears all standard 
demethylation of the genome
Doege et al.29 2012 Mice Fibroblasts Tet2 Generation of 
5-hydroxymethylcytosine 
(5hmC) through the 
oxidation of 5mC
Hydroxylation of pluripotency 
sites (Nanog and Esrrb) favoring 
a greater number of iPSCs
Costa et al.30 2013 Mice Embryonic Tet1/Tet2 Physical interaction with 
Nanog
Hydroxylation of pluripotency 
sites (Oct4 and Esrrb)
Gao et al.31 2013 Mice Fibroblasts Tet1 DNA demethylation and 
activation of Oct4
Better induction of 
pluripotency
iPSCs: induced pluripotent stem cells.
TABLE 2 Epigenetic changes in histones.
Authors Year Species Type of cell Technology Epigenetic changes Results
Huangfu et al.44 2008 Mice Fibroblasts VPA/TSA/SAHA Inhibitor of histone 
deacetylation
Prevents histone deacetylation, 
increasing reprogramming efficiency by 
more than 100X compared to OSKM
Shi et al.43 2008 Mice Fibroblasts BIX-01294 G9a methyltransferase 
inhibitor
Reduces histone H3K9 methylation, 
facilitating transcription. Improves 
reprogramming efficiency compared to 
Oct4 and Klf4
Esteban et al.35 2010 Humans Fibroblasts Vitamin C Nanog promoter, Oct4/ 
Histone demethylation
Decreases senescence during 
reprogramming
Liang et al.46 2010 Mice Fibroblasts Sodium butyrate Histone deacetylase 
(HDAC) inhibitor
Facilitates reprogramming mediated by 
c-Myc
Liang et al.48 2012 Mice Fibroblasts Lentivirus increasing 
the expression of 
Kdm2b
Activation of genes in 
the initial phase of 
reprogramming
Decreased H3K36me2 levels, 
contributing to reprogramming
Onder et al.47 2012 Mice Fibroblasts epz004777 DOT1L inhibitor
(Histone 
methyltransferase 
specific for H3K79)
With the reduction of DOT1L, a 
reduction in the methylation of H3K79 
occurs, improving the reprogramming 
by increasing transcription factors such 
as Nanog and Lin28
Chen et al.45 2013 Mice Fibroblasts Vitamin C Increases Kdm3 and 
Kdm4 – Lysine-specific 
demethylase
Reduces H3K9me2 and H3K9me3, 
important early in the reprogramming 
of iPSCs
Hou et al.42 2013 Mice Fibroblasts 3-deazaneplanocin 
A (Dznep)
Histone 
methyltransferase 
inhibitor
Better reprogramming occurs with 
inhibition of histone methyltransferase 
by preventing methylation in the 
arginine and lysine residues of histones
OSKM: Oct4, Sox2, Klf4 and c-Myc; VPA/TSA/SAHA: valproic acid/trichostatin A/suberoylanilide hydroxamic acid; iPSCs: induced pluripotent stem cells.
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TABLE 3 Epigenetic changes using microRNAs.
Authors Year miRNA Species Type of cell Mechanism of action Results
Judson et al.54 2009 290-295 Mice Fibroblast Blocks p21, leading to 
increased cell cycle proteins
Promotes the G1-S phase transition 
(proliferation), indirectly activating 
pluripotency factors
Li and He50 2012 Let-7 Mice Embryonic 
stem cell
Reduced CyclinD/Cdk4 
regulation
Blocks G1-S phase
Subramanyam et 
al.; Lin et al.55,56
2011 302-367 Mice Fibroblast Inhibits TGFII-β Promotes MET
Choi et al.63 2011 34a and 
34b/c
Mice Fibroblast Reduced regulation of p21 
and p53
Indirectly blocks pluripotency factors
Li et al.61 2014 135b Mice Fibroblast Reduced expression of 
TGF-β, Igfbp5, and Wisp1
Promotes MET
Zare et al.49 2015 124-128 Humans Fibroblast Regulate the development  
of neurons
Promotes the migration, maturation 
and differentiation of neurons, 
maintaining adequate gene expression 
and repressing unwanted genes
MET: mesenchymal-epithelial transition.
thology affects around 700,000 people in Japan, and is 
the most common form of blindness in people aged over 
60, causing progressive loss of the retinal pigment epi-
thelial monolayer. The transplant lasted around two hours 
and, according to the researchers, the patient did not 
suffer adverse effects, and there were an improvement in 
the morphology of the macula and neovascularization.66
This clinical trial was carried out by the group of Pro-
fessor Takahashi, co-author of the manuscripts that won 
Professor Yamanaka the Nobel Prize in Medicine in 2012. 
However, in March 2015, clinical testing intended to treat 
six patients was suspended due to regulatory changes in 
regenerative medicine in Japan.67
Other clinical trials are currently underway to test 
the effectiveness of cellular therapy with iPSC in the treat-
ment of AMD, Parkinson’s disease, spinal cord injury, 
diabetes and myocardial infarction.68 Preliminary results 
have not yet been presented. 
Maintenance of the epigenetic factors of the iPSC 
after reprogramming has also been used to understand 
the molecular pathways involved in the development of 
diseases, development of new drugs and personalized 
medicine.69 The first study conducted of this kind used 
a model of neuropathic disease. The authors repro-
grammed fibroblasts from patients with Riley-Day syn-
drome and monitored in vitro splicing of the IKBKAP 
(mutation associated with the disorder). Furthermore, 
the researchers also evaluated candidate drugs for rever-
sal of the splicing. The study of iPSC gains relevance in 
this case, due to the inability of accessing the tissues 
affected by Riley-Day syndrome.70 Other studies have 
been developed along this line,69 and are promising in 
the context of drug development. Figure 2 summarizes 
the use of iPSC.
conclusion 
Despite the improvement recently seen in iPSC reprogram-
ming by up to 100 times, when compared to Yamanaka 
factors,44 the yield remains relatively low and high costs. 
Another problem is the long period for full iPSC repro-
gramming and the high cells proliferation rates associ-
ated with a greater chance of developing cancer.71 Takahashi 
and Yamanaka suggest considering using iPSC with al-
logeneic transplantation in regenerative medicine, which 
would improve the effectiveness of the treatment of certain 
diseases such as spinal cord injury, which requires quick 
treatment without waiting for the time taken for repro-
gramming.11 Furthermore, there is a need for better un-
derstanding of how the reprogramming interventions 
influence the epigenetic memory of the reprogrammed 
cells. Despite advances in iPSC reprogramming, certain 
questions have emerged: 1) Is it possible to completely 
erase the somatic epigenetic memory by associating the 
different treatments mentioned?; 2) Could “forced” repro-
gramming cause long-term damage, such as the develop-
ment of cancer or other diseases?; 3) Is it possible to replace 
embryonic stem cells with iPSC in regenerative medicine? 
In spite of the extraordinary progress achieved recently in 
the use of iPSC, the deepening of ongoing studies and 
realization of new studies are necessary in order to elucidate 
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the mechanisms of the aforementioned changes, optimiz-
ing their application in regenerative medicine.
resuMo
Células-tronco de pluripotência induzida: papel da epi-
genética na reprogramação e sua aplicabilidade clínica
As células-tronco de pluripotência induzida (CTPI) ou do 
inglês induced pluripotent stem cells (iPSCs) são células so-
máticas reprogramadas para o estado embrionário por 
meio da expressão de fatores ectópicos de transcrição 
específicos, tornando-as um alvo promissor para a medi-
cina regenerativa. Apesar das CTPI compartilharem ca-
racterísticas embrionárias, como pluripotência e capaci-
dade de autorrenovação, elas possuem uma baixa 
eficiência de reprogramação, sendo a memória epigené-
tica uma das principais barreiras nesse processo. A epige-
nética é caracterizada por alterações reversíveis e herdáveis 
no genoma funcional que não alteram a sequência de 
nucleotídeos do DNA. Dentre as diferentes modificações 
epigenéticas, destacam-se metilação de DNA, alterações 
em histonas e microRNA. Atualmente, sabe-se que o pro-
cesso de reprogramação efetivo das CTPI envolve um 
completo remodelamento da memória epigenética somá-
tica existente, seguido pelo estabelecimento de uma “as-
sinatura epigenética” que esteja de acordo com o novo 
tipo de célula a ser diferenciada. Modificações epigenéti-
cas personalizadas são capazes de melhorar o rendimen-
to e a efetividade das CTPI geradas, abrindo uma nova 
perspectiva para a terapia celular. Nesta revisão reunimos 
as principais informações sobre os fatores epigenéticos 
que afetam a reprogramação das CTPI, bem como seus 
benefícios na aplicação da terapia celular. 
Palavras-chave: células-tronco de pluripotência induzida, 
medicina regenerativa, reprogramação celular, epigenética, 
histonas, microRNA.
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